CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record.

Tilianin improves lipid profile and alleviates atherosclerosis in ApoE−/− mice through up-regulation of SREBP2-mediated LDLR expression

Du, Yu, Xi, Mei, Li, Yihua, Zheng, Ruifang, Ding, Xiaotian, Li, Xingxing, Zhang, Xiumin, Wang, Li, Xing, Jianguo, Hong, Bin·2023·Phytomedicine
DOI 10.1016/j.phymed.2022.154577
Open this paper in CoChat — free account

Abstract

Background The huge global burden of atherosclerotic cardiovascular diseases (CVDs) represents an urgent unmet need for the development of novel therapeutics. Dracocephalum moldavica L. has been used as a traditional Uygur medicine to treat various CVDs for centuries. Tilianin is a major flavonoid component of D. moldavica L. and has potential for preventing atherosclerosis. However, the molecular mechanisms that tilianin attenuate atherosclerosis are far from fully understood. Purposes The purpose of this study is to investigate the efficiency and underlying mechanisms of tilianin in controlling lipid profile and preventing atherogenesis. Methods The lipid-lowering effect of tilianin was evaluated in C57BL/6 and ApoE -/- mice by systematically determining serum biochemical parameters. The effects of tilianin on the atherosclerotic lesion were observed in aortic roots and whole aortas of ApoE -/- mice with oil red O staining. Caecal content from ApoE -/- mice were collected for 16S rRNA gene sequence analysis to assess the structure of the gut microbiota. The inhibition of hepatosteatosis was verified by histological examination, and a liver transcriptome analysis was performed to elucidate the tilianin-induced hepatic transcriptional alterations. Effects of tilianin on the expression and function of LDLR were examined in HepG2 cells and ApoE -/- mice. Further mechanisms underlying the efficacy of tilianin were investigated in HepG2 cells. Results Tilianin treatment improved…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.phymed.2022.154577

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. Akanda, 2019, The biological and pharmacological roles of polyphenol flavonoid tilianin, Eur. J. Pharmacol., 842, 291, 10.1016/j.ejphar.2018.10.044 · DOI
  2. Cao, 2013, Ameliorated effect of Dracocephalum total flavones on experimental atherosclerosis in rats, Chin. Hosp. Pham., 33, 1570
  3. Cao, 2013, Effects of tilianin on the level of serum lipids and inflammatory factors in rats, Chin. J. Exp. Tradit. Med. Formulae, 19, 164
  4. Chua, 2020, Squalene monooxygenase: a journey to the heart of cholesterol synthesis, Prog. Lipid. Res., 79, 10.1016/j.plipres.2020.101033 · DOI
  5. Dadu, 2014, Lipid lowering with PCSK9 inhibitors, Nat. Rev. Cardiol., 11, 563, 10.1038/nrcardio.2014.84 · DOI
  6. Dai, 2015, Triple recycling processes impact systemic and local bioavailability of orally administered flavonoids, AAPS J., 17, 723, 10.1208/s12248-015-9732-x · DOI
  7. DeBose-Boyd, 2018, SREBPs in lipid metabolism, insulin signaling, and beyond, Trends Biochem. Sci., 43, 358, 10.1016/j.tibs.2018.01.005 · DOI
  8. Du, 2020, Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice, Br. J. Pharmacol., 177, 1754, 10.1111/bph.14933 · DOI
  9. Eberlé, 2004, SREBP transcription factors: master regulators of lipid homeostasis, Biochimie, 86, 839, 10.1016/j.biochi.2004.09.018 · DOI
  10. García-Díaz, 2016, Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats, Biomed. Pharmacother., 83, 667, 10.1016/j.biopha.2016.07.023 · DOI
  11. Härdtner, 2021, New insights in statins affecting atheromatous plaque macrophages, Curr. Opin. Lipidol., 32, 258, 10.1097/MOL.0000000000000769 · DOI
  12. Hong, 2001, Inhibition of cytokine-induced vascular cell adhesion molecule-1 expression; possible mechanism for anti-atherogenic effect of Agastache rugosa, FEBS Lett., 495, 142, 10.1016/S0014-5793(01)02379-1 · DOI
  13. Hu, 2021, Report on cardiovascular health and diseases burden in China: an updated summary of 2020. Chin, Circ. J., 36, 521
  14. Jukema, 2019, Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies, BMC Med., 17, 197, 10.1186/s12916-019-1433-3 · DOI
  15. Kaakoush, 2015, Insights into the role of Erysipelotrichaceae in the human host, Front. Cell. Infect. Microbiol., 5, 84, 10.3389/fcimb.2015.00084 · DOI · Paper page
  16. Kim, 2019, Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia, Front. Microbiol., 10, 1947, 10.3389/fmicb.2019.01947 · DOI
  17. Klein-Szanto, 2019, Keep recycling going: new approaches to reduce LDL-C, Biochem. Pharmacol., 164, 336, 10.1016/j.bcp.2019.04.003 · DOI · Paper page
  18. Lagace, 2014, PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells, Curr. Opin. Lipidol., 25, 387, 10.1097/MOL.0000000000000114 · DOI · Paper page
  19. Li, 2017, Identification of a novel liver X receptor agonist that regulates the expression of key cholesterol homeostasis genes with distinct pharmacological characteristics, Mol. Pharmacol., 91, 264, 10.1124/mol.116.105213 · DOI
  20. Maimaitiyiming, 2014, The treatment of Uygur medicine Dracocephalum moldavica L on chronic mountain sickness rat model, Pharmacogn. Mag., 10, 477, 10.4103/0973-1296.141817 · DOI
  21. Mbikay, 2014, Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture, FEBS Open Bio, 4, 755, 10.1016/j.fob.2014.08.003 · DOI
  22. Michos, 2019, Lipid management for the prevention of atherosclerotic cardiovascular disease, N. Engl. J. Med., 381, 1557, 10.1056/NEJMra1806939 · DOI
  23. Moon, 2012, Quercetin up-regulates LDL receptor expression in HepG2 cells, Phytother. Res., 26, 1688, 10.1002/ptr.4646 · DOI
  24. Mourikis, 2020, Lipid lowering therapy in cardiovascular disease: From myth to molecular reality, Pharmacol. Ther., 213, 10.1016/j.pharmthera.2020.107592 · DOI
  25. Nam, 2005, Inhibition of cytokine-induced IκB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice, Atherosclerosis, 180, 27, 10.1016/j.atherosclerosis.2004.11.022 · DOI
  26. Nam, 2006, Inhibitory effects of tilianin on the expression of inducible nitric oxide synthase in low density lipoprotein receptor deficiency mice, Exp. Mol. Med., 38, 445, 10.1038/emm.2006.52 · DOI
  27. Ochiai, 2016, Kaempferol stimulates gene expression of low-density lipoprotein receptor through activation of Sp1 in cultured hepatocytes, Sci. Rep., 6, 24940, 10.1038/srep24940 · DOI
  28. Sato, 1996, Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2, J. Biol. Chem., 271, 26461, 10.1074/jbc.271.43.26461 · DOI
  29. Shen, 2019, Atheroprotective mechanisms of tilianin by inhibiting inflammation through down-regulating NF-κB pathway and foam cells formation, Front. Physiol., 10, 825, 10.3389/fphys.2019.00825 · DOI
  30. Smith, 2019, Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice, BMC Microbiol., 19, 130, 10.1186/s12866-019-1494-7 · DOI
  31. Soyal, 2015, Targeting SREBPs for treatment of the metabolic syndrome, Trends Pharmacol. Sci., 36, 406, 10.1016/j.tips.2015.04.010 · DOI
  32. Südhof, 1987, Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene, J. Biol. Chem., 262, 10773, 10.1016/S0021-9258(18)61030-0 · DOI · Paper page
  33. Urban, 2013, Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis, Am. Coll. Cardiol., 62, 1401, 10.1016/j.jacc.2013.07.056 · DOI
  34. Veseli, 2017, Animal models of atherosclerosis, Eur. J. Pharmacol., 816, 3, 10.1016/j.ejphar.2017.05.010 · DOI · Paper page
  35. Vieira-Silva, 2020, Statin therapy is associated with lower prevalence of gut microbiota dysbiosis, Nature, 581, 310, 10.1038/s41586-020-2269-x · DOI
  36. Xing, 2013, Effects of total flavonoids from Dracocephalum moldavica on the proliferation, migration, and adhesion molecule expression of rat vascular smooth muscle cells induced by TNF-α, Pharm. Biol., 51, 74, 10.3109/13880209.2012.711839 · DOI
  37. Zheng, 2020, Total flavones of Dracocephalum moldavica L. protect astrocytes against H2O2-induced apoptosis through a mitochondria-dependent pathway, BMC Complement. Med. Ther., 20, 78, 10.1186/s12906-020-2846-4 · DOI

Cited by

Sorted by citations

Metadata

Authors
Du, Y., Xi, M., Li, Y., Zheng, R., Ding, X., Li, X., Zhang, X., Wang, L., Xing, J., & Hong, B.
Venue
Phytomedicine
Publisher
Elsevier BV
Published
2023-01
Volume
109
Pages
154577
ISSN
0944-7113
DOI
10.1016/j.phymed.2022.154577
Cited by
21
References
0
Language
en
Licence
Funders
  • Beijing Municipal Science and Technology Commission
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Chinese Academy of Medical Sciences & Peking Union Medical College

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review